Chugai Pharmaceutical (OTCMKTS:CHGCY) Posts Earnings Results

Key Points

• Chugai Pharmaceutical reported quarterly EPS of $0.27, with a 23.76% return on equity and a 35.09% net margin.
• Shares rose 1.2% to open at $21.79; the stock has a $71.72 billion market capitalization, a 23.41 P/E ratio and a 52-week range of $18.33 to $34.84.
• Analyst sentiment remains positive but cautious, with one Strong Buy, one Buy and three Hold ratings, resulting in a consensus rating of “Moderate Buy.”

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.27 earnings per share (EPS) for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.

Chugai Pharmaceutical Stock Up 1.2%

Shares of Chugai Pharmaceutical stock opened at $21.79 on Tuesday. Chugai Pharmaceutical has a 52-week low of $18.33 and a 52-week high of $34.84. The company's 50-day simple moving average is $20.75 and its 200-day simple moving average is $24.66. The firm has a market cap of $71.72 billion, a price-to-earnings ratio of 23.41 and a beta of 0.60.

Analyst Upgrades and Downgrades

CHGCY has been the subject of a number of recent research reports. UBS Group cut Chugai Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 6th. Nomura upgraded Chugai Pharmaceutical to a "hold" rating in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy".

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company's principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.